Dr. Sohi on the future of PSMA-PET imaging in prostate cancer

EP: 1.Harnessing the Full Power of PSMA-PET Requires Multidisciplinary Approach

EP: 2.Dr. Spratt on the importance of a multidisciplinary approach to PSMA-PET

EP: 3.PSMA-PET leads imaging breakthroughs in prostate cancer paradigm

EP: 4.Conventional imaging obstacles that PSMA-PET overcomes

EP: 5.Dr. Sohi on the timing of PSMA-PET imaging in prostate cancer

EP: 6.Dr. Sohi on why PSMA-PET results can alter treatment plans

Now Viewing

EP: 7.Dr. Sohi on the future of PSMA-PET imaging in prostate cancer

EP: 8.Approval sought for TLX007-CDx in prostate cancer

EP: 9.[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer

EP: 10.Dr. Helfand on the potential role for PSMA-PET imaging in active surveillance

EP: 11.Dr. Helfand on escalation/de-escalation of treatment based on PSMA-PET

EP: 12.Dr. Helfand on potential future directions with PET imaging

EP: 13.The evolving role of PSMA-PET along the continuum of prostate cancer

EP: 14.Study compares imaging methods for MDT in oligorecurrent prostate cancer

EP: 15.Unlocking the potential of PSMA-PET: The need for interdisciplinary collaboration in image interpretation

EP: 16.Dr. Koontz on how PSMA-PET improves targeted treatment strategies

EP: 17.PSMA PET/CT can reveal prostate cancer recurrences before biochemical criteria met

EP: 18.Jason Hafron, MD on the disruptive nature of PSMA-PET imaging

EP: 19.Jason Hafron, MD, on PSMA-PET in oligometastatic disease

EP: 20.Jeremie Calais, MD, on rationale for reporting template for PSMA-PET scans

In this video, Jaideep S. Sohi, MD, shares his vision for the future of PSMA-PET imaging in prostate cancer. Sohi is a nuclear medicine physician with Northwestern University and American Molecular Imaging.

Transcription

PSMA-PET has only been around for about 3 years, give or take, and you can see it's already made a tremendous impact in utilization and impacting patient care. It has facilitated more accurate staging and restaging of these patients with prostate carcinoma. I think the utilization of this modality, this tracer, will only increase when we look down the road 5 to 10 years from now. I think it is feasible to see PSMA-PET being used at an even earlier time point, which would mean using this imaging modality in conjunction with MRI to evaluate patients with signs and symptoms that are concerning for potential prostate carcinoma (rising or abnormal PSA levels) to basically help diagnose the patient. And there might even be the potential that one day PSMA-PET imaging could actually replace MRI, but that is yet to be determined.

Transcription has been edited for clarity.